Anebulo Pharmaceuticals Q1 EPS $(0.10) Beats $(0.12) Estimate
Portfolio Pulse from Benzinga Newsdesk
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported Q1 EPS losses of $(0.10), surpassing the consensus estimate of $(0.12) by 16.67%. This represents a 9.09% improvement from the $(0.11) per share loss reported in the same quarter last year.
November 14, 2023 | 9:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anebulo Pharmaceuticals reported a smaller-than-expected loss per share in Q1, beating estimates and showing year-over-year improvement.
Beating EPS estimates typically has a positive impact on investor sentiment and can lead to a short-term increase in stock price. The improvement over the previous year's loss further strengthens the positive outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100